reptides › focus › pinealon

pinealon

epithalon's sister from the same russian lab. neuroprotection claims, even thinner data.

tier C · focus · Russia Khavinson '00s

verdict

epithalon's sister peptide from the same Russian lab. neuroprotection claims, even thinner data.

if you're asking about pinealon for cognition or memory — the in vitro neuroprotection data is real but single-source. the rodent ischemia-recovery work is more specific than vague nootropic marketing suggests, but it doesn't carry the cognitive-enhancement claims vendors attach. zero independent Western clinical trials. zero confirmed human pharmacokinetics. community reports are sparse and indistinguishable from placebo.

if you're asking what the actual mechanism looks like — in cultured neurons, suppresses reactive oxygen species and necrotic cell death. in aged rat behavioral models and after carotid occlusion in stroke-adjacent research, shows neuroprotective effects. the mechanistic angle (oxidative-stress protection, ischemia recovery) is more honest than the 'memory peptide' framing. it's stroke-adjacent biology, not nootropic biology.

if you came in via the Khavinson longevity-peptide narrative — the longevity-mitochondrial-nootropic space leans on Russian-only research and industry-press claims. pinealon sits at the thin end of even that literature. the actual evidence for the actual product sold online is close to nothing. the niche appeal is the theoretical 'brain peptide' framing within the Khavinson lineage, not the clinical record.

based on published evidence and disclosed clinical practice. not medical advice.

why C-tier

C-tier because the compound sits almost entirely on theoretical plausibility and single-lab publications, with minimal clinical data even by Russian-research standards and no independent replication. The parent research program (Khavinson bioregulators) is real, and the in vitro work has some substance. But the leap from 'in vitro effects and theoretical BBB penetration' to the 'neuroprotective nootropic' product sold online is not supported by meaningful human evidence. Not D-tier because the underlying research program is legitimate and the mechanistic claims aren't absurd. They're just not demonstrated.

the core tension

Pinealon is one of Khavinson's short peptides, a three-amino-acid compound (Glu-Asp-Arg) claimed to penetrate the blood-brain barrier and exert neuroprotective effects. The biology of short peptides crossing the BBB is plausible. The specific evidence that pinealon does so, in humans, at clinically meaningful doses, with meaningful neuroprotective outcomes, is mostly not there. It's in the same Khavinson ecosystem as epithalon, real research program, real published literature, basically no independent replication.

what it is

pinealon is a synthetic tripeptide, glutamate-aspartate-arginine (Glu-Asp-Arg), developed by the Khavinson group as part of the broader 'short bioregulator' program of tissue-specific signaling peptides. positioned as a brain-tissue bioregulator. plasma half-life is minutes.

what it does

in cultured neurons, suppresses reactive oxygen species and necrotic cell death. in aged rat behavioral models and after carotid occlusion in stroke-adjacent research, shows neuroprotective and ischemia-recovery effects. theoretical case for blood-brain-barrier penetration based on size and charge. human cognitive or pharmacokinetic data is absent.

origin

developed at the St. Petersburg Institute of Bioregulation and Gerontology, same program that produced epithalon. published almost entirely by the originating group and affiliated networks. no independent Western clinical trials.

why researchers are interested

users who report effects describe subtle clarity changes, nothing dramatic. cheap, short cycles, no major safety signals from limited community adoption. the niche appeal is the theoretical 'brain peptide' framing within the Khavinson lineage.

does it work

the longevity-mitochondrial-nootropic space leans on Russian-only research and industry-press claims, and pinealon sits at the thin end of even that literature. the in vitro neuroprotection data is real but single-source. the rodent ischemia-recovery work is more specific than vague nootropic marketing suggests, but it doesn't carry the cognitive-enhancement claims vendors attach. zero independent Western clinical trials. zero confirmed human pharmacokinetics. community reports are sparse and indistinguishable from placebo. the mechanistic angle (oxidative-stress protection, ischemia recovery) is more honest than the 'memory peptide' framing. the actual evidence for the actual product sold online is close to nothing.

claims vs the data

  • crosses the blood-brain barrier — partially true — Short peptides can cross the BBB in principle, and some Khavinson-group work argues pinealon does. Independent verification at clinically relevant doses in humans is not established.
  • protects neurons against oxidative stress — weak — In vitro neuroprotection data exists in the Khavinson literature. Translation to in vivo or clinical effect in humans is not demonstrated outside the originating lab.
  • improves cognitive function in humans — unverified — No meaningful human clinical trial data. Community reports exist but are sparse and inconsistent compared to better-validated nootropics like semax.
  • useful in age-related cognitive decline — overreach — Marketing claim based on extrapolation from the Khavinson bioregulator thesis, not on any clinical trial specifically demonstrating pinealon benefit in dementia or MCI populations.

key facts

  • molecular formula: C15H26N6O8
  • molecular weight: 418.4 Da
  • amino acids: 3
  • half-life: minutes in plasma; the claim of prolonged CNS effects is not well-quantified
  • type: synthetic tripeptide (bioregulator-class, Khavinson lab)
  • CAS: 289656-45-7
  • 1 originating research group
  • ~0 independent clinical replication
  • 0 FDA approvals
  • in vitro most mechanism data

frequently asked questions

What is pinealon?

Pinealon is a synthetic tripeptide (Glutamic acid-Aspartic acid-Arginine) developed by Vladimir Khavinson's research group in Russia. It is positioned as a pineal-gland-derived cognitive and neuroprotective peptide.

What does pinealon do?

Preclinical and Khavinson-network clinical-adjacent literature suggests neuroprotective and anti-stress biology. Community users report improvements in mental clarity, focus, and resilience to cognitive fatigue, but the evidence base is much thinner than semax.

How is pinealon typically administered?

Subcutaneous injection in research peptide community use. Russian research has used intramuscular and oral administration in various protocols. There is no FDA-approved dosing.

What are the side effects of pinealon?

Side effect reports are minimal, consistent with most short Russian-developed peptides. Occasional injection-site reactions. Human clinical safety data is limited compared to semax or selank.

Is pinealon FDA approved?

No. Pinealon has no FDA approval and no widespread pharmaceutical distribution. It appears mainly in Khavinson-network gerontology and neurology research rather than in a broad, independently replicated clinical program.

How much does pinealon cost?

No US clinical retail price. On the research-chemical market it is inexpensive.

related peptides

  • epithalon — sister peptide from the same Khavinson program
  • semax — better-validated Russian nootropic with regulatory approval
  • dihexa — other 'BBB-penetrant neuroprotectant' claim with thin evidence

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.